{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:13:31Z","timestamp":1792631611235,"version":"4.5.0"},"reference-count":51,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has led to profound and durable tumor responses in a relevant subset of patients with relapsed\/refractory (r\/r) B-cell lymphomas. Still, some patients show insufficient benefit or relapse after CAR T-cell therapy. We performed a retrospective study to investigate the correlation between CAR T-cell persistence in the peripheral blood (PB) at 6 months, assessed by droplet digital PCR (ddPCR), with CAR T-cell treatment outcome. 92 patients with r\/r B-cell lymphomas were treated with CD19-targeting CAR T-cell therapies at our institution between 01\/2019\u201308\/2022. Six months post-treatment, 15 (16%) patients had no detectable circulating CAR-T constructs by ddPCR. Patients with CAR T-cell persistence had a significantly higher CAR T-cell peak (5432 vs. 620 copies\/ug cfDNA, p = 0.0096), as well as higher incidence of immune effector cell-associated neurotoxicity syndrome (37% vs. 7%, p = 0.0182). After a median follow-up of 8.5 months, 31 (34%) patients relapsed. Lymphoma relapses were less frequent among patients with CAR T-cell persistence (29% vs. 60%, p = 0.0336), and CAR T-cell persistence in the PB at 6 months was associated with longer progression-free survival (PFS) (HR 2.79, 95% CI: 1.09\u20137.11, p = 0.0319). Moreover, we observed a trend towards improved overall survival (OS) (HR 1.99, 95% CI: 0.68\u20135.82, p = 0.2092) for these patients. In our cohort of 92 B-cell lymphomas, CAR T-cell persistence at 6 months was associated with lower relapse rates and longer PFS. Moreover, our data confirm that 4-1BB-CAR T-cells have a longer persistence as compared to CD-28-based CAR T-cells.<\/jats:p>","DOI":"10.3390\/ijms24065688","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T03:33:57Z","timestamp":1679024037000},"page":"5688","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4206-4294","authenticated-orcid":false,"given":"Valerie","family":"Wittibschlager","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-1573","authenticated-orcid":false,"given":"Katja","family":"Seipel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2515-1935","authenticated-orcid":false,"given":"Naomi","family":"Porret","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2259-1011","authenticated-orcid":false,"given":"Gertrud","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haslebacher","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8138-0505","authenticated-orcid":false,"given":"Michael","family":"Daskalakis","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1639-3059","authenticated-orcid":false,"given":"Dilara","family":"Akhoundova","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland"},{"name":"Center of Hemato-Oncology, University Cancer Center, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/CCO.0000000000000668","article-title":"CD19-Directed CAR T-Cell Therapy in B-Cell NHL","volume":"32","author":"Kersten","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive Factors of Early Progression after CAR T-Cell Therapy in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/d41573-019-00051-6","article-title":"Non-Hodgkin Lymphoma Therapy Landscape","volume":"18","author":"Chaudhari","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","first-page":"372","article-title":"Mechanisms of Resistance to CAR T Cell Therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.3892\/ol.2017.6589","article-title":"Upfront High-Dose Chemotherapy Combined with Autologous Stem Cell Transplantation: Potential Survival Benefit for Patients with High-Risk Diffuse Large B-Cell Lymphoma","volume":"14","author":"Nakaya","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gkazi, S.A., Gravett, E., Bautista, C., Bartram, J., Ghorashian, S., and Adams, S.P. (2022). Clinically Applicable Assessment of Tisagenlecleucel CAR T Cell Treatment by Digital Droplet PCR for Copy Number Variant Assessment. IJMS, 23.","DOI":"10.3390\/ijms23147573"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Myers, G.D., Verneris, M.R., Goy, A., and Maziarz, R.T. (2021). Perspectives on Outpatient Administration of CAR-T Cell Therapy in Aggressive B-Cell Lymphoma and Acute Lymphoblastic Leukemia. J. Immunother. Cancer, 9.","DOI":"10.1136\/jitc-2020-002056"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Martino, M., Naso, V., Loteta, B., Canale, F.A., Pugliese, M., Alati, C., Musuraca, G., Nappi, D., Gaimari, A., and Nicolini, F. (2022). Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon. IJMS, 23.","DOI":"10.3390\/ijms232113332"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pietrobon, V., Todd, L.A., Goswami, A., Stefanson, O., Yang, Z., and Marincola, F. (2021). Improving CAR T-Cell Persistence. IJMS, 22.","DOI":"10.3390\/ijms221910828"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and Ferritin in Addition to the EASIX Score Predict CAR-T\u2013Related Toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical Pharmacology of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-Long Leukaemia Remissions with Persistence of CD4+ CAR T Cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11845-020-02264-w","article-title":"Cellular Immunotherapies for Cancer","volume":"190","author":"Hayes","year":"2021","journal-title":"Ir. J. Med. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1200\/EDBK_320085","article-title":"CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions","volume":"41","author":"Gill","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_15","unstructured":"Novak, U. (2022, December 28). CAR-T-Zellen Bei Lymphomen. Available online: https:\/\/gesundheit-heute.ch\/wp-content\/uploads\/2021\/05\/CAR-T-Therapie-Lymphom-Brosch\u00fcre.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of Response and Mechanisms of Resistance of CAR T-Cell Therapy in Multiple Myeloma","volume":"2","author":"Themeli","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/bloodadvances.2020004038","article-title":"Absolute Lymphocyte Count Proliferation Kinetics after CAR T-Cell Infusion Impact Response and Relapse","volume":"5","author":"Faude","year":"2021","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mika, T., Maghnouj, A., Klein-Scory, S., Ladigan-Badura, S., Baraniskin, A., Thomson, J., Hasenkamp, J., Hahn, S.A., Wulf, G., and Schroers, R. (2020). Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00084"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular Kinetics of CTL019 in Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.omtm.2019.12.018","article-title":"Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel","volume":"16","author":"Fehse","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Badbaran, A., Berger, C., Riecken, K., Kruchen, A., Geffken, M., M\u00fcller, I., Kr\u00f6ger, N., Ayuk, F.A., and Fehse, B. (2020). Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR. Cancers, 12.","DOI":"10.3390\/cancers12071970"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lu, A., Liu, H., Shi, R., Cai, Y., Ma, J., Shao, L., Rong, V., Gkitsas, N., Lei, H., and Highfill, S.L. (2020). Application of Droplet Digital PCR for the Detection of Vector Copy Number in Clinical CAR\/TCR T Cell Products. J. Transl. Med., 18.","DOI":"10.1186\/s12967-020-02358-0"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/bloodadvances.2020003959","article-title":"Axicabtagene Ciloleucel in Vivo Expansion and Treatment Outcome in Aggressive B-Cell Lymphoma in a Real-World Setting","volume":"5","author":"Ayuk","year":"2021","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","article-title":"The Pharmacology of T Cell Therapies","volume":"8","author":"Milone","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cam4.3686","article-title":"Relmacabtagene Autoleucel (Relma-cel) CD19 CAR-T Therapy for Adults with Heavily Pretreated Relapsed\/Refractory Large B-cell Lymphoma in China","volume":"10","author":"Ying","year":"2021","journal-title":"Cancer Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sugimoto, H., Chen, S., Minembe, J.-P., Chouitar, J., He, X., Wang, H., Fang, X., and Qian, M.G. (2021). Insights on Droplet Digital PCR\u2013Based Cellular Kinetics and Biodistribution Assay Support for CAR-T Cell Therapy. AAPS J., 23.","DOI":"10.1208\/s12248-021-00560-6"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/eji.202049064","article-title":"CAR T Cells: Building on the CD19 Paradigm","volume":"51","author":"Eshhar","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Penack, O., and Koenecke, C. (2020). Complications after CD19+ CAR T-Cell Therapy. Cancers, 12.","DOI":"10.3390\/cancers12113445"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14712598.2020.1729735","article-title":"Assessment and Management of Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T Cell Therapy","volume":"20","author":"Chou","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Denlinger, N., Bond, D., and Jaglowski, S. (2022). CAR T-Cell Therapy for B-Cell Lymphoma. Curr. Probl. Cancer, 46.","DOI":"10.1016\/j.currproblcancer.2021.100826"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"G\u00f6ssi, S., Bacher, U., Haslebacher, C., Nagler, M., Suter, F., Staehelin, C., Novak, U., and Pabst, T. (2022). Humoral Responses to Repetitive Doses of COVID-19 MRNA Vaccines in Patients with CAR-T-Cell Therapy. Cancers, 14.","DOI":"10.3390\/cancers14143527"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Byrne","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Cerrano, M., Ruella, M., Perales, M.-A., Vitale, C., Faraci, D.G., Giaccone, L., Coscia, M., Maloy, M., Sanchez-Escamilla, M., and Elsabah, H. (2020). The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research into Clinical Practice. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00888"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An Introduction to Chimeric Antigen Receptor (CAR) T-cell Immunotherapy for Human Cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_41","unstructured":"Master, D.A. (2022, December 28). Kymriah vs. Yescarta [UPDATED]. Available online: https:\/\/nucleusbiologics.com\/resources\/kymriah-vs-yescarta\/."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological Updates: Neurological Complications of CAR-T Therapy","volume":"268","author":"Tallantyre","year":"2021","journal-title":"J. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T Cell Antitumor Activity by Reducing MTORC1 Activity and Preserving Their Stem Cell Memory Phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Feng, D., Wang, C., Zhang, Y., Zhao, C., Li, S., Qin, Y., Chang, A.H., and Zhu, J. (2022). Administration of Granulocyte-Macrophage Colony-Stimulating Factor Enhanced Chimeric Antigen Receptor T-Cell Expansion and Cellular Immunity Recovery without Inducing Cytokine Release Syndrome. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1042501"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Battram, A.M., Bachiller, M., Lopez, V., Fern\u00e1ndez de Larrea, C., Urbano-Ispizua, A., and Mart\u00edn-Antonio, B. (2021). IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15\/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. Cancers, 13.","DOI":"10.3390\/cancers13143534"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-140120","article-title":"High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics","volume":"136","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Rentsch, V., Seipel, K., Banz, Y., Wiedemann, G., Porret, N., Bacher, U., and Pabst, T. (2022). Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. Cancers, 14.","DOI":"10.3390\/cancers14102516"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.exphem.2020.07.003","article-title":"Analysis of IL-6 Serum Levels and CAR T Cell-Specific Digital PCR in the Context of Cytokine Release Syndrome","volume":"88","author":"Pabst","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5688\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:56:41Z","timestamp":1760122601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24065688"],"URL":"https:\/\/doi.org\/10.3390\/ijms24065688","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}